View Filing Data

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2014	May 07, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Celsion CORP
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		17,217,066
Amendment Flag	false
Entity Central Index Key	0000749647
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1

Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 4,606,267	$ 5,718,504
Investment securities – available for sale, at fair value	47,255,487	37,156,381
Accrued interest receivable on investment securities	339,791	212,048
Advances, deposits and other current assets	620,979	675,186
Total current assets	52,822,524	43,762,119
Property and equipment (at cost, less accumulated depreciation of $1,349,690 and $1,264,190, respectively)	747,386	832,886
Other assets:
Deposits, deferred fees and other assets	1,120,931	1,054,942
Patent licensing fees, net	18,750	20,625
Total other assets	1,139,681	1,075,567
Total assets	54,709,591	45,670,572
Current liabilities:
Accounts payable	2,102,013	1,452,436
Accrued liabilities	2,205,838	2,707,653
Notes payable - current portion	439,218	10,891
Deferred revenue - current portion	500,000	500,000
Total current liabilities	5,247,069	4,670,980
Common stock warrant liability		3,026
Notes payable – non-current portion	4,560,782	5,000,000
Deferred revenue - non-current portion	3,875,000	4,000,000
Other non-current liabilities	467,545	472,731
Total liabilities	14,150,396	14,146,737
Stockholders' equity:
Common stock, $0.01 par value; 75,000,000 shares authorized; 17,347,665 and 13,737,970 shares issued at March 31, 2014 and December 31, 2013, and 17,217,066 and 13,604,975 shares outstanding at March 31, 2014 and December 31, 2013, respectively	173,477	137,380
Additional paid-in capital	217,535,506	203,139,142
Accumulated other comprehensive loss	(27,897)	(44,166)
Accumulated deficit	(174,744,150)	(169,287,157)
Subtotal	42,936,936	33,945,199
Treasury stock, at cost (130,599 and 132,995 shares at March 31, 2014 and December 31, 2013, respectively)	(2,377,741)	(2,421,364)
Total stockholders' equity	40,559,195	31,523,835
Total liabilities and stockholders' equity	$ 54,709,591	$ 45,670,572

Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2009
Accumulated Depreciation (in Dollars)	$ 1,349,690	$ 1,264,190
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	17,347,665	13,737,970	224,239
Common stock, shares outstanding	17,217,066	13,604,975
Treasury stock, shares	130,599	132,995

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
Statements of Operations (Unaudited) - USD ($)	Mar. 31, 2014	Mar. 31, 2013
Net Loss [Member]
Operating expenses:
Loss from operations	$ (5,422,693)	$ (650,974)
Non-cash deemed dividend from beneficial conversion feature on convertible preferred stock		(4,601,410)
Licensing revenue	125,000	125,000
Research and development	2,893,168	3,203,177
General and administrative	2,433,857	1,688,729
Total operating expenses	5,327,025	4,891,906
Loss from operations	(5,202,025)	(4,766,906)
Net loss attributable to common shareholders	$ (5,422,693)	$ (5,252,384)
Net loss attributable to common shareholders per common share – basic and diluted (in Dollars per share)	$ (0.33)	$ (0.55)
Weighted average shares outstanding – basic and diluted (in Shares)	16,371,097	9,554,668
Other income (expense):
Gain from change in valuation of common stock warrant liability	$ 3,026	$ 4,280,297
Investment income, net	7,019	16,563
Interest expense	(230,713)	(180,928)
Total other (expense) income, net	$ (220,668)	$ 4,115,932

Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Net loss	$ (5,422,693)	$ (650,974)
Changes in:
Realized loss on investment securities recognized in investment income, net	20,610	53,740
Unrealized loss on investment securities	(4,341)	(85,689)
Other comprehensive gain (loss)	16,269	(31,949)
Total comprehensive loss	$ (5,406,424)	$ (682,923)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Statements of Cash Flows - USD ($)	3 Months Ended
Statements of Cash Flows - USD ($)	Mar. 31, 2014	Mar. 31, 2013
Common Stock Warrants (Member)
Cash flows from financing activities:
Proceeds from exercise of common stock warrants		$ 261,944
Net loss	$ (5,422,693)	(650,974)
Depreciation and amortization	87,375	76,875
Change in fair value of common stock warrant liability	(3,026)	(4,280,297)
Deferred revenue	(125,000)	(125,000)
Stock-based compensation	607,230	263,192
Treasury shares issued for services and 401(k) matching contribution	9,323	20,835
Change in deferred rent liability	(5,186)	(3,829)
Deferred finance charges	89,675	31,560
Deposits, advances, other current assets and other assets	(229,200)	(225,660)
Accounts payable	649,577	1,841,037
Accrued liabilities	(501,815)	(157,534)
Cash received for non-refundable research and development fee		5,000,000
Net cash (used in) provided by operating activities:	(4,843,740)	1,790,205
Purchases of investment securities	(17,862,837)	(20,245,204)
Proceeds from sale and maturity of investment securities	7,780,000	3,048,000
Net cash used in investing activities	(10,082,837)	(17,197,204)
Proceeds from sale of common stock equity, net of issuance costs	13,825,231	6,711,173
Proceeds from sale of preferred stock, net of issuance costs		13,648,663
Proceeds from exercise of options to purchase common stock		174,871
Principal payments on notes payable	(10,891)	(14,461)
Net cash provided by financing activities	13,814,340	20,782,190
Decrease in cash and cash equivalents	(1,112,237)	(5,375,191)
Cash and cash equivalents at beginning of period	5,718,504	14,991,488
Cash and cash equivalents at end of period	4,606,267	20,366,679
Supplemental disclosures of cash flow information:
Interest paid	$ 141,038	$ 180,928

Note 1 - Business Description

3 Months Ended

Mar. 31, 2014

Disclosure Text Block [Abstract]

Nature of Operations [Text Block]

Note 1. Business Description

Celsion Corporation, referred to herein as “Celsion”, “we”, or “the Company,” a Delaware corporation based in Lawrenceville, New Jersey, is an oncology drug development company focused on improving treatment for those suffering with difficult-to-treat forms of cancer. We are working to develop and commercialize more efficient, effective, targeted chemotherapeutic oncology drugs based on our proprietary heat-activated liposomal technology. Our lead product ThermoDox®, is being tested in human clinical trials for the treatment of primary liver cancer and recurrent chest wall breast cancer.

Note 2 - Basis of Presentation

3 Months Ended

Mar. 31, 2014

Disclosure Text Block [Abstract]

Basis of Presentation and Significant Accounting Policies [Text Block]

Note 2. Basis of Presentation

The accompanying unaudited financial statements of Celsion have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.

In the opinion of management, all adjustments, consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying unaudited financial statements. Operating results for the three month period ended March 31, 2014 are not necessarily indicative of the results that may be expected for any other interim period(s) or for any full year. For further information, refer to the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 13, 2014 with the Securities and Exchange Commission.

The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from those estimates.

Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the financial statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the financial statements other than those arising in the ordinary course of business.

Note 3 - New Accounting Pronouncements

3 Months Ended

Mar. 31, 2014

Disclosure Text Block [Abstract]

Description of New Accounting Pronouncements Not yet Adopted [Text Block]

Note 3. New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by Financial Accounting Standards Board (FASB) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to our operations.

Note 4 - Net Loss Per Common Share

3 Months Ended

Mar. 31, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

Note 4. Net Loss per Common Share

Basic earnings per share is calculated based upon the net income (loss) available to common shareholders divided by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated after adjusting the denominator of the basic earnings per share computation for the effects of all dilutive potential common shares outstanding during the period. The dilutive effects of preferred stock, options and warrants and their equivalents are computed using the treasury stock method.

On October 28, 2013, the Company effected a 4.5-to-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on October 29, 2013. Immediately prior to the reverse stock split, the Company had 61,226,873 shares of common stock outstanding were combined and converted into 13,604,975 shares of the Company’s common stock as a result of the reverse stock split. All share, and per share amounts related to common stock, preferred stock, stock options, warrants and restricted stock included in these financial statements have been restated to reflect the reverse stock split. In addition, in accordance with Accounting Standards Update (ASU) No. 2010-01, Equity (Topic 505): Accounting for Distributions to Shareholders with Components of Stock and Cash, the changes in the Company’s common stock as a result of the reverse stock split require the per share components of the current and prior period financial statements presented be based on the new number of shares. Therefore, net loss per common share for the three months ended March 31, 2013 has been adjusted to reflect post reverse stock split shares.

For the three months ended March 31, 2014 and 2013, diluted loss per common share was the same as basic loss per common share as all options and warrants that were convertible into shares of the Company’s common stock were excluded from the calculation of diluted earnings per share as their effect would have been anti-dilutive. The total number of shares of common stock issuable upon exercise of warrants and equity awards for the three month periods ended March 31, 2014 and 2013 were 6,244,886 and 4,685,862, respectively.

Note 5 - Investment Securities - Available For Sale

3 Months Ended

Mar. 31, 2014

Investments, Debt and Equity Securities [Abstract]

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

Note 5. Investment Securities - Available For Sale

Investment securities available for sale of $47,255,487 and $37,156,381 as of March 31, 2014 and December 31, 2013, respectively, consist of commercial paper and corporate debt securities. They are valued at fair value, with unrealized gains and losses reported as a separate component of Stockholders’ Equity in Accumulated Other Comprehensive Loss.

Investment securities available for sale are evaluated periodically to determine whether a decline in their value is other than temporary. The term “other than temporary” is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near-term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. Once a decline in value is determined to be other than temporary, the value of the security is reduced and a corresponding charge to earnings is recognized.

A summary of the cost, fair value and bond maturities of the Company’s investment securities is as follows:

	March 31, 2014				December 31, 2013
	Cost		Fair Value		Cost		Fair Value
Corporate bond maturities
Within 3 months	$	11,798,892	$	11,750,665	$	7,799,033	$	7,797,689
Between 3-12 months		35,484,492		35,504,822		29,401,514		29,358,692
Total	$	47,283,384	$	47,255,487	$	37,200,547	$	37,156,381

The following table shows the Company’s investment securities with unrealized holding gains and losses and their fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at March 31, 2014 and December 31, 2013. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary.

	March 31, 2014					December 31, 2013
Description of Securities	Fair Value		Unrealized Holding Gains (Losses)			Fair Value		Unrealized Holding Gains (Losses)

Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Bonds – corporate issuances with unrealized gains	$	4,366,735	$	97		$	6,650,095	$	1,907
Bonds – corporate issuances with unrealized losses		42,888,752		(27,994	)		30,506,286		(46,073	)
Total	$	47,255,487	$	(27,897	)	$	37,156,381	$	(44,166	)

Investment income which includes interest and dividends and gross realized gains and losses on sales of available for sale securities is summarized as follows:

	Three Months Ended March 31,
Description of Securities	2014			2013

Interest and dividend income	$	27,629		$	70,303
Realized losses		(20,610	)		(53,740	)
	$	7,019		$	16,563

The following table presents the change, by component, in accumulated other comprehensive loss for the first three months of 2014.

	Accumulated Other Comprehensive Loss
Balance at January 1, 2014	$	(44,166	)

Unrealized losses on investment securities		(4,341	)
Realized loss reclassified from other accumulated comprehensive loss		20,610
Net other comprehensive loss, net		16,269

Balance at March 31, 2014	$	(27,897	)

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Note 6 - Fair Value of Measurements

3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

Note 6. Fair Value of Measurements

FASB Accounting Standards Codification (ASC) Section 820 (formerly SFAS No. 157) “Fair Value Measurements and Disclosures,” establishes a three level hierarchy for fair value measurements which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:

Level 1: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date;

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and

Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions that market participants would use in pricing an asset or liability.

The fair values of securities available for sale are determined by obtaining quoted prices on nationally recognized exchanges (Level 1 inputs) or matrix pricing, which is a mathematical technique widely used in the industry to value debt securities without relying exclusively on quoted prices for the specific securities but rather by relying on the securities’ relationship to other benchmark quoted securities (Level 2 inputs). The common stock warrant liability has been valued using the Black-Scholes option pricing model, the inputs of which are more fully described in Note 11 to the financial statements.

Cash and cash equivalents, other current assets, accounts payable and other accrued liabilities are reflected in the balance sheet at their estimated fair values primarily due to their short-term nature.

The following table presents information about assets and liabilities recorded at fair value on a recurring basis as of March 31, 2014 and December 31, 2013 on the Company’s Balance Sheets:

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets /Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
As of March 31, 2014
Short-term investments available for sale Bonds – corporate issuances	$	47,255,487	$	47,255,487	$	─	$	─

As of December 31, 2013
Short-term investments available for sale Bonds – corporate issuances	$	37,156,381	$	37,156,381	$	─	$	─

Liabilities:
As of March 31, 2014
Common stock warrant liability	$	─	$	─	$	─	$	─

As of December 31, 2013
Common stock warrant liability	$	3,026	$	─	$	─	$	3,026

There were no transfers of assets or liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during the three months ended March 31, 2014.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 7 - Accrued Liabilities

3 Months Ended

Mar. 31, 2014

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 7. Accrued Liabilities

Accrued liabilities at March 31, 2014 and December 31, 2013 include the following:

	March 31, 2014		December 31, 2013
Amounts due to contract research organizations and other contractual agreements	$	1,411,249	$	1,711,934
Accrued payroll and related benefits		661,151		900,434
Accrued professional fees		65,000		63,500
Accrued interest on notes payable		48,438	─
Other		20,000		31,785

Total accrued liabilities	$	2,205,838	$	2,707,653

Note 8 - Note Payable

3 Months Ended

Mar. 31, 2014

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

Note 8. Note Payable

Hercules Credit Agreement

In November 2013, the Company entered into a loan agreement with Hercules Technology Growth Capital, Inc. (“Hercules”) which permits up to $20 million in capital to be distributed in multiple tranches (the “Hercules Credit Agreement”). The Company drew the first tranche of $5 million upon closing of the Hercules Credit Agreement in November 2013 and used approximately $4 million of the proceeds to repay the outstanding obligations under its loan agreement with Oxford Finance LLC and Horizon Technology Finance Corporation as discussed further below. The Company anticipates that it will use any additional funding up to $15 million as provided under the agreement for working capital or in support of its previously announced strategic acquisition initiative, which is designed to identify new technologies and clinical stage products for its development pipeline.

The obligations under the Hercules Credit Agreement are in the form of secured indebtedness bearing interest at a calculated prime-based variable rate (11.25% per annum since inception). Payments under the loan agreement are interest only for the first twelve months after loan closing, followed by a 30-month amortization period of principal and interest through the scheduled maturity date.

As a fee in connection with the Hercules Credit Agreement, the Company issued Hercules a warrant exercisable for a total of 194,986 shares of the Company’s common stock (the “Hercules Warrant”) at a per share exercise price of $3.59, with 50% immediately exercisable for cash or by net exercise from November 25, 2013 and the remaining 50% to be exercisable upon Hercules funding any subsequent tranches. The Hercules Warrant will expire November 25, 2018. Hercules has certain rights to register the common stock underlying the Hercules Warrant pursuant to a Registration Rights Agreement with the Company dated November 25, 2013. The registration rights expire on the date when such stock may be sold under Rule 144 without restriction or upon the first year anniversary of the registration statement for such stock, whichever is earlier.

The Company valued the Hercules Warrant using the Black-Scholes option pricing model and recorded $521,763 in 2013 as deferred financing fees. In calculating the value of the warrants, the Company assumed a volatility rate of 102%, risk free interest rate of 1.37%, an expected life of 5 years, a stock price of $3.55 (closing price on date of the Hercules Warrant) and no expected forfeitures nor dividends. In connection with the Hercules Credit Agreement, the Company incurred cash expenses of $352,378 which were also recorded as deferred financing fees. These deferred financing fees are being amortized as interest expense using the effective interest method over the life of the loan. For the first three months of 2014, the Company incurred $140,625 in interest expense and amortized $89,676 in deferred financing fees as interest expense in connection with the Hercules Credit Agreement.

The Hercules Credit Agreement contains customary covenants, including covenants that limit or restrict the Company’s ability to grant liens, incur indebtedness, make certain restricted payments, merge or consolidate and make dispositions of assets. Upon the occurrence of an event of default under the Hercules Credit Agreement, the lenders may cease making loans, terminate the Hercules Credit Agreement, declare all amounts outstanding to be immediately due and payable and foreclose on or liquidate the Company’s assets that comprise the lenders’ collateral. The Hercules Credit Agreement specifies a number of events of default (some of which are subject to applicable grace or cure periods), including, among other things, non-payment defaults, covenant defaults, a material adverse effect on the Company or its assets, cross-defaults to other material indebtedness, bankruptcy and insolvency defaults and material judgment defaults. The Company has maintained compliance with these covenants.

Following is a schedule of future principle payments due on the Hercules Credit Agreement:

For the year ending March 31:	Hercules Credit Agreement

2015	$	439,218
2016		1,878,096
2017		2,104,767
2018		577,919

Total	$	5,000,000

Oxford & Horizon Credit Agreement

In June 2012, the Company entered into a Loan and Security Agreement (the “Oxford & Horizon Credit Agreement”) with Oxford Finance LLC (“Oxford”) and Horizon Technology Finance Corporation (“Horizon”). The Oxford & Horizon Credit Agreement provided for a secured term loan of up to $10 million, with 50% of any loans to be funded by Oxford and 50% to be funded by Horizon. The aggregate loan amount could have been advanced in two tranches of $5 million each. The first tranche (the “Term A Loan”) was made available to the Company on June 27, 2012 and the second tranche was to be made available, if at all, during the period beginning on the date that the Company achieved positive data in its Phase III clinical trial of RFA and ThermoDox® (the “HEAT Study”) and ending on March 31, 2013. On January 31, 2013, the Company announced it did not meet the primary endpoint of the HEAT Study.

The Term A Loan was originally scheduled to mature on October 15, 2015. As a result of the Hercules Credit Agreement discussed above, the Company terminated the Oxford & Horizon Credit Agreement and repaid the outstanding principle, accrued interest and termination fees totaling approximately $4.1 million.

The proceeds of the Oxford & Horizon Credit Agreement were used to fund the Company’s working capital and general corporate purposes. The obligations under the Oxford & Horizon Credit Agreement were secured by substantially all assets of the Company other than its intellectual property and certain other agreed-upon exclusions.

As a fee in connection with the Oxford & Horizon Credit Agreement, the Company issued warrants to Horizon and Oxford (the “Oxford & Horizon Warrants”) to purchase the number of shares of the Company’s common stock equal to 3% of each loan amount divided by the exercise price of $13.14 per share, which was calculated as the average NASDAQ closing price of the Company’s common stock for the three days prior to the funding of the loan amount. This resulted in 11,415 warrant shares issued in connection with the Term A Loan. The Oxford & Horizon Warrants issued in connection with the Term A Loan are exercisable for cash or by net exercise and will expire seven years after their issuance, which is June 27, 2019.

The Company valued the Oxford & Horizon Warrants using the Black-Scholes option pricing model and recorded $73,654 as deferred financing fees. In calculating the value of the warrants, the Company assumed a volatility rate of 74.3%, risk free interest rate of 1.10%, an expected life of 3.5 years, a stock price of $12.60 which was the closing price on date of issuing the Oxford & Horizon Warrant) and no expected forfeitures nor dividends. In connection with the Oxford & Horizon Credit Agreement, the Company incurred cash expenses of $217,715 which were recorded as deferred financing fees in 2012. These deferred financing fees were amortized as interest expense over the life of the loan. During the first three months of 2013, the Company paid $146,874 in interest expense and amortized $31,560 of deferred financing fees as interest expense. The Term A Loan bore interest at a fixed rate of 11.75%.

Capital Lease

In November 2011, the Company financed $144,448 of lab equipment through a capital lease. This lease obligation has thirty monthly payments of $5,651 through February 2014. During the first quarter of 2014, the Company made principal and interest payments totaling $11,303 to satisfy the remaining obligation under this capital lease.

Note 9 - Stockholders' Equity

3 Months Ended

Mar. 31, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 9. Stockholders’ Equity

January 2014 Common Stock Offering

On January 15, 2014, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company sold, in a registered offering, an aggregate of 3,603,604 shares of its common stock, par value $0.01 per share, and warrants to purchase up to 1,801,802 shares of Common Stock, for an aggregate purchase price of approximately $15 million (the “January 2014 Common Stock Offering”). The shares of common stock and warrants were sold in units, with each unit consisting of one share of common stock, a Series A warrant to purchase 0.25 share of common stock and a Series B warrant to purchase 0.25 share of common stock. Each unit was sold at a purchase price of $4.1625. Each Series A warrant will be exercisable at any time on or after its issuance date and until the five-year anniversary of the issuance date. Each Series B warrant will be exercisable at any time on or after its issuance date and until the one-year anniversary of the issuance date. Each warrant has an exercise price of $4.10 per share. Under the purchase agreement, the Company is prohibited, for a period of nine months after the closing, from effecting or entering into an agreement to issue common stock or any other securities that are at any time convertible into, or exercisable or exchangeable for, or otherwise entitle the holder thereof to receive, common stock to the extent such issuance or sale involves certain variable conversion, exercise or exchange prices or such agreement provides for sale of securities at a price to be determined in the future.

Controlled Equity Offering

On February 1, 2013, the Company entered into a Controlled Equity Offering^SM Sales Agreement (the “ATM Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its common stock having an aggregate offering price of up to $25.0 million (the “ATM Shares”) pursuant to the Company’s previously filed and effective Registration Statement on Form S-3. Under the ATM Agreement, Cantor may sell ATM Shares by any method deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Capital Market, on any other existing trading market for the our common stock or to or through a market maker. From February 1, 2013 through February 25, 2013, the Company sold and issued an aggregate of 1,195,927 shares of common stock under the ATM Agreement, receiving approximately $6.8 million in net proceeds.

The Company is not obligated to sell any ATM Shares under the ATM Agreement. Subject to the terms and conditions of the ATM Agreement, Cantor will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The NASDAQ Capital Market, to sell ATM Shares from time to time based upon the Company’s instructions, including any price, time or size limits or other customary parameters or conditions the Company may impose. In addition, pursuant to the terms and conditions of the ATM Agreement and subject to the instructions of the Company, Cantor may sell ATM Shares by any other method permitted by law, including in privately negotiated transactions.

The ATM Agreement will terminate upon the earlier of (i) the sale of ATM Shares under the ATM Agreement having an aggregate offering price of $25 million and (ii) the termination of the ATM Agreement by Cantor or the Company. The ATM Agreement may be terminated by Cantor or the Company at any time upon 10 days' notice to the other party, or by Cantor at any time in certain circumstances, including the occurrence of a material adverse change in the Company. The Company pays Cantor a commission of 3.0% of the aggregate gross proceeds from each sale of ATM Shares and has agreed to provide Cantor with customary indemnification and contribution rights. The Company also reimbursed Cantor for legal fees and disbursements, of $50,000, in connection with entering into the ATM Agreement. In connection with the January 2014 Common Stock Offering, the Company agreed to not sell any ATM Shares until July 22, 2014.

February 2013 Preferred Stock Offering

On February 22, 2013, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company sold, in a registered offering, an aggregate of 15,000.00422 shares of its Series A 0% convertible preferred stock and the warrants to purchase shares of its common stock, for an aggregate purchase price of approximately $15.0 million (the “February 2013 Preferred Stock Offering”). The closing of the February 2013 Preferred Stock Offering occurred on February 26, 2013, in which the Company received approximately $15.0 million in gross proceeds. Subject to certain ownership limitations, shares of Series A 0% convertible preferred stock are convertible, at the option of the holder thereof, into an aggregate of up to 2,682,764 shares of common stock, and the warrants are exercisable to purchase an aggregate of up to 1,341,382 shares of common stock. Each warrant has an exercise price of $5.31 per share, equal to the closing bid price of common stock on February 21, 2013. The warrants are immediately exercisable and expire five years after the date of issuance.

Upon issuance, we estimated the fair value of the warrants issued in the February 2013 Preferred Stock Offering to be approximately $5.4 million using the Black-Scholes pricing model. Also, upon issuance, we recognized a one-time, non-cash deemed dividend related to the beneficial conversion feature connected to the preferred stock in the Preferred Stock Offering of approximately $4.6 million in the first three months of 2013.

Assumptions used in the valuation of the warrants issued in the February 2013 Preferred Stock Offering are as follows:

Risk-free interest rate	0.78	%
Expected volatility	102.23	%
Expected life (in years)	5.0
Expected forfeiture rate	0.0	%
Expected dividend yield	0.00	%

During 2013, 2,682,764 shares of common stock in the aggregate were issued upon conversion of all of the 15,000.00422 shares of the Series A 0% convertible preferred stock.

May 2013 Common Stock Offering

On May 30, 2013, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company sold, in a registered offering, an aggregate of 1,392,109 shares of its common stock for an aggregate purchase price of approximately $9.8 million.

Reverse Stock Split

On October 28, 2013, the Company effected a 4.5-to-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on October 29, 2013. As of October 28, 2013, each nine shares of issued and outstanding common stock and equivalents were combined and converted into two shares of common stock outstanding at the time of the reverse stock split. Weighted average shares outstanding and loss attributable to common stockholders of the Company for the three months ended March 31, 2013 have been adjusted to reflect the reverse stock split.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Note 10 - Stock Based Compensation

3 Months Ended

Mar. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note 10. Stock Based Compensation

Stock Options Plans

The Company has long-term compensation plans that permit the granting of incentive awards in the form of stock options. Generally, the terms of these plans require that the exercise price of the options may not be less than the fair market value of Celsion’s common stock on the date the options are granted. Options granted generally vest over various time frames or upon milestone accomplishments. The Company’s options generally expire ten years from the date of the grant.

In 2007, the Company adopted the Celsion Corporation 2007 Stock Incentive Plan (the “2007 Plan”) under which 222,222 shares were authorized for issuance. The purpose of the 2007 Plan is to promote the long-term growth and profitability of the Company by providing incentives to improve stockholder value and enable the Company to attract, retain and reward the best available persons for positions of substantial responsibility. The 2007 Plan permits the granting of equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, phantom stock, and performance awards, or in any combination of the foregoing. At the Annual Meetings of Stockholders of Celsion held on June 25, 2010 and June 7, 2012, the stockholders approved amendments to the Plan. The only material difference between the original Plan and the amended Plan was the number of shares of common stock available for issuance under the amended Plan which was increased by 222,222 to a total of 444,444 shares in 2010 and by 500,000 to a total of 944,444 shares in 2012.

Prior to the adoption of the 2007 Plan, the Company adopted two stock plans for directors, officers and employees (one in 2001 and another in 2004) under which 148,148 shares were reserved for future issuance under each of these plans. As these plans have been superseded by the 2007 Plan, any options previously granted which expire, forfeit, or cancel under these plans will be rolled into the 2007 Plan.

The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Celsion’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate.

The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model:

	Three Months Ended March 31,
	2014			2013

Risk-free interest rate		2.75	%		0.85	%
Expected volatility		100.72	%		83.41	%
Expected life (in years)		10.00			5.25
Expected forfeiture rate		5	%		5	%
Expected dividend yield		0.0	%		0.0	%

Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. The risk free interest rate is derived from values assigned to U.S. Treasury bonds as published in the Wall Street Journal in effect at the time of grant. The model incorporates exercise, pre-vesting and post-vesting forfeiture assumptions based on analysis of historical data. The expected life of the fiscal 2014 and 2013 grants was generated using the simplified method.

A summary of the Company’s stock option and restricted stock awards for the three months ended March 31, 2014 is as follows:

	Stock Options					Restricted Stock Awards
Equity Awards	Options Outstanding			Weighted Average Exercise Price		Non-vested Restricted Stock Outstanding			Weighted Average Grant Date Fair Value		Weighted Average Contractual Terms of Equity Awards (in years)

Equity awards outstanding at December 31, 2013		861,905		$	12.30		2,112		$	16.29
Equity awards granted		323,200		$	3.66		4,500		$	3.72
Equity awards exercised	–			–			(6,091	)	$	8.00
Equity awards forfeited, cancelled or expired		(10,555	)	$	34.14	–			–

Equity awards outstanding at March 31, 2014		1,174,550		$	9.72		521		$	4.63		6.95

Aggregate intrinsic value of outstanding awards at March 31, 2014	$	–				$	1,756

Equity awards exercisable at March 31, 2014		779,446		$	12.07							5.74

Aggregate intrinsic value of awards exercisable at March 31, 2014	$	–

Total compensation cost related to employee stock options and restricted stock awards amounted to $607,230 and $263,192 for the three months ended March 31, 2014 and 2013, respectively. No compensation cost related to share-based payments arrangements was capitalized as part of the cost of any asset as of March 31, 2014 and 2013.

As of March 31, 2014, there was $1.2 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 2.1 years. The weighted average grant-date fair value was $3.31 and $3.92 per share for the options granted during the three months ended March 31, 2014 and 2013, respectively. The weighted average grant-date fair value was $3.72 for the restricted stock awards granted during the three months ended March 31, 2014. The Company granted 4,500 restricted stock awards during the first three months of 2014. No restricted stock grants were issued in the first three months of 2013.

Collectively, for all the stock option plans as of March 31, 2014, there were a total of 1,189,528 shares reserved, which were comprised of 1,175,071 equity awards granted and 14,457 equity awards available for future issuance.

Note 11 - Warrants

3 Months Ended

Mar. 31, 2014

Warrants [Abstract]

Warrants [Text Block]

Note 11. Warrants

Common Stock Warrants

Following is a summary of all warrant activity for the first three months of 2014:

Warrants	Number of Warrants Issued		Weighted Average Exercise Price

Warrants outstanding at December 31, 2013		3,268,013	$	10.43

Warrants granted in connection with the January 2014 Common Stock Offering, as more fully described in Note 9		1,801,802	$	4.10

Warrants exercised for common stock	–		–

Warrants outstanding at March 31, 2014		5,069,815	$	8.18

Aggregate intrinsic value of outstanding warrants at March 31, 2014	$	-

Weighted average remaining contractual terms (in years)		3.13

Common Stock Warrant Liability

In September 2009, the Company closed a registered direct offering with a select group of institutional investors that raised gross proceeds of $7.1 million and net proceeds of $6.3 million. In connection with this registered direct offering, the Company issued 448,478 shares of its common stock and warrants to purchase 224,239 shares of common stock. The warrants have an exercise price of $23.58 per share and are exercisable at any time on or after the six month anniversary of the date of issuance and on or prior to 66 months after the date of issuance. Under the terms of the warrants, upon certain transactions, including a merger, tender offer or sale of all or substantially all of the assets of the Company, each warrant holder may elect to receive a cash payment in exchange for the warrant, in an amount determined by application of the Black-Scholes option valuation model. Accordingly, pursuant to ASC 815.40, Derivative Instruments and Hedging - Contracts in Entity’s Own Equity, the warrants are recorded as a liability and then marked to market each period through the Statement of Operations in other income or expense. At the end of each subsequent quarter, the Company will revalue the fair value of the warrants and the change in fair value will be recorded as a change to the warrant liability and the difference will be recorded through the Statement of Operations in other income or expense.

The fair value of the warrants at March 31, 2014 and December 31, 2013 was $-0- and $3,026, respectively, calculated using the Black-Scholes option-pricing model with the following ranges of assumptions:

	March 31, 2014			December 31, 2013

Risk-free interest rate		0.13	%		0.13	%
Expected volatility		64.74	%		64.74	%
Expected life (in years)		1.25			1.25
Expected forfeiture rate		0.0	%		0.0	%
Expected dividend yield		0.00	%		0.00	%

The following is a summary of the changes in the common stock warrant liability for the three months ended March 31, 2014:

Beginning balance as of January 1, 2014	$	3,026
Gain from the adjustment for the change in fair value included in net income		(3,026	)
Ending balance as of March 31, 2014	$	–

Note 12 - Contingent Liabilities and Commitments

3 Months Ended

Mar. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Note 12. Contingent Liabilities and Commitments

In July 2011, the Company, as a tenant, and a landlord executed a lease (the “Lease”) for a 10,870 square foot premises located in Lawrenceville, New Jersey. In October 2011, the Company relocated its offices to Lawrenceville, New Jersey from Columbia, Maryland. The Lease has a term of 66 months and provides for 6 months of free rent; with the first monthly rent payment of approximately $23,000 paid in April 2012. Also, as required by the Lease, the Company provided Brandywine with an irrevocable and unconditional standby letter of credit for $250,000, which the Company secured with an escrow deposit at its banking institution of this same amount. The standby letter of credit will be reduced by $50,000 on each of the 19th, 31st and 43rd months from the initial term, with the remaining $100,000 amount remaining until the Lease Term has expired. In connection with the $50,000 reduction of the standby letter of credit in April 2013, the Company reduced the escrow deposit by $50,000.

Note 13 - Technology Development and Licensing Agreements

3 Months Ended

Mar. 31, 2014

Licensing Transaction [Abstract]

Licensing Transaction [Text Block]

Note 13. Technology Development and Licensing Agreements

Technology Development Contract and Commercial Supply Agreement with Zhejiang Hisun Pharmaceutical Co. Ltd.

On May 7, 2012 the Company entered into a long term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. (“Hisun”) for the production of ThermoDox® in mainland China, Hong Kong and Macau (the “China territory”). In accordance with the terms of the agreement, Hisun will be responsible for providing all of the technical and regulatory support services, including the costs of all technical transfer, registration and bioequivalence studies, technical transfer costs, Celsion consultative support costs and the purchase of any necessary equipment and additional facility costs necessary to support capacity requirements for the manufacture of ThermoDox®. Celsion will repay Hisun for the aggregate amount of these development costs and fees commencing on the successful completion of three registration batches of ThermoDox®. Hisun is also obligated to certain performance requirements under the agreement. The agreement will initially be limited to a percentage of the production requirements of ThermoDox® in the China territory with Hisun retaining an option for additional global supply after local regulatory approval in the China territory. In addition, Hisun will collaborate with Celsion around the regulatory approval activities for ThermoDox® with the China State Food and Drug Administration (CHINA FDA). As of March 31, 2014, the Company has incurred approximately $371,000 in costs to be reimbursed to Hisun.

On January 18, 2013, we entered into a technology development contract with Hisun, pursuant to which Hisun paid us a non-refundable research and development fee of $5 million to support our development of ThermoDox® in the China territory. Following our announcement on January 31, 2013 that the HEAT study failed to meet its primary endpoint, Celsion and Hisun have agreed that the Technology Development Contract entered into on January 18, 2013 will remain in effect while the parties continue to collaborate and are evaluating the next steps in relation to ThermoDox®, which include the sub-group analysis of patients in the Phase III HEAT Study for the hepatocellular carcinoma clinical indication and other activities to further the development of ThermoDox® for the Greater China market. The $5.0 million received as a non-refundable payment from Hisun in the first quarter 2013 has been recorded to deferred revenue and will continue to be amortized over the 10 year term of the agreement, until such time as the parties find a mutually acceptable path forward on the development of ThermoDox® based on findings of the ongoing post-study analysis of the HEAT Study data.

On July 19, 2013, the Company and Hisun entered into a Memorandum of Understanding to pursue ongoing collaborations for the continued clinical development of ThermoDox® as well as the technology transfer relating to the commercial manufacture of ThermoDox® for the China territory. This expanded collaboration includes development of the next generation liposomal formulation with the goal of creating safer, more efficacious versions of marketed cancer chemotherapeutics.

Among the key provisions of the Celsion-Hisun Memorandum of Understanding are:

●

Hisun will provide the Company with non-dilutive financing and the investment necessary to complete the technology transfer of its proprietary manufacturing process and the production of registration batches for the China territory;

●

Hisun will collaborate with the Company around the clinical and regulatory approval activities for ThermoDox® as well as other liposomal formations with the CHINA FDA; and

●

Hisun will be granted a right of first offer for a commercial license to ThermoDox® for the sale and distribution of ThermoDox® in the China territory.

Development, Product Supply and Commercialization Agreement with Yakult Honsha

In the fourth quarter of 2008, the Company entered into a Development, Product Supply and Commercialization Agreement with Yakult Honsha under which Yakult was granted the exclusive right to commercialize and market ThermoDox® for the Japanese market. We were paid a $2.5 million up-front licensing fee and we have the potential to receive additional payments from Yakult upon receipt of marketing approval by the Japanese Ministry of Health, Labor and Welfare as well as upon the achievement of certain levels of sales and approval for new indications. We will receive double digit escalating royalties on the sale ThermoDox® in Japan, when and if any such sales occur. We also will be the exclusive supplier of ThermoDox® to Yakult.

In January 2011, the Company amended its Development, Product Supply and Commercialization Agreement with Yakult to provide for up to $4.0 million in an accelerated partial payment to the Company of a future drug approval milestone, which included $2.0 million paid to the Company upon the closing of the preferred equity financing the Company conducted in January 2011 and an additional $2.0 million conditioned upon the resumption of enrollment of Japanese patients in the Japan cohort of the HEAT Study. In consideration of these accelerated milestone payments from Yakult, the Company agreed to reduce future drug approval milestone payments by approximately forty percent (40%).

Note 5 - Investment Securities - Available For Sale (Tables)

3 Months Ended

Mar. 31, 2014

Investments, Debt and Equity Securities [Abstract]

Available-for-sale Securities [Table Text Block]

	March 31, 2014				December 31, 2013
	Cost		Fair Value		Cost		Fair Value
Corporate bond maturities
Within 3 months	$	11,798,892	$	11,750,665	$	7,799,033	$	7,797,689
Between 3-12 months		35,484,492		35,504,822		29,401,514		29,358,692
Total	$	47,283,384	$	47,255,487	$	37,200,547	$	37,156,381

Schedule of Unrealized Loss on Investments [Table Text Block]

	March 31, 2014					December 31, 2013
Description of Securities	Fair Value		Unrealized Holding Gains (Losses)			Fair Value		Unrealized Holding Gains (Losses)

Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Bonds – corporate issuances with unrealized gains	$	4,366,735	$	97		$	6,650,095	$	1,907
Bonds – corporate issuances with unrealized losses		42,888,752		(27,994	)		30,506,286		(46,073	)
Total	$	47,255,487	$	(27,897	)	$	37,156,381	$	(44,166	)

Investment Income [Table Text Block]

	Three Months Ended March 31,
Description of Securities	2014			2013

Interest and dividend income	$	27,629		$	70,303
Realized losses		(20,610	)		(53,740	)
	$	7,019		$	16,563

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Accumulated Other Comprehensive Loss
Balance at January 1, 2014	$	(44,166	)

Unrealized losses on investment securities		(4,341	)
Realized loss reclassified from other accumulated comprehensive loss		20,610
Net other comprehensive loss, net		16,269

Balance at March 31, 2014	$	(27,897	)

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Note 6 - Fair Value of Measurements (Tables)

3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets /Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
As of March 31, 2014
Short-term investments available for sale Bonds – corporate issuances	$	47,255,487	$	47,255,487	$	─	$	─

As of December 31, 2013
Short-term investments available for sale Bonds – corporate issuances	$	37,156,381	$	37,156,381	$	─	$	─

Liabilities:
As of March 31, 2014
Common stock warrant liability	$	─	$	─	$	─	$	─

As of December 31, 2013
Common stock warrant liability	$	3,026	$	─	$	─	$	3,026

Note 7 - Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2014

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

	March 31, 2014		December 31, 2013
Amounts due to contract research organizations and other contractual agreements	$	1,411,249	$	1,711,934
Accrued payroll and related benefits		661,151		900,434
Accrued professional fees		65,000		63,500
Accrued interest on notes payable		48,438	─
Other		20,000		31,785

Total accrued liabilities	$	2,205,838	$	2,707,653

Note 8 - Note Payable (Tables)

3 Months Ended

Mar. 31, 2014

Debt Disclosure [Abstract]

Schedule of Maturities of Long-term Debt [Table Text Block]

For the year ending March 31:	Hercules Credit Agreement

2015	$	439,218
2016		1,878,096
2017		2,104,767
2018		577,919

Total	$	5,000,000

Note 9 - Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2014

Prefered Stock [Member]

Note 9 - Stockholders' Equity (Tables) [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Assumptions used in the valuation of the warrants issued in the February 2013 Preferred Stock Offering are as follows:

Risk-free interest rate	0.78	%
Expected volatility	102.23	%
Expected life (in years)	5.0
Expected forfeiture rate	0.0	%
Expected dividend yield	0.00	%

Note 10 - Stock Based Compensation (Tables)

3 Months Ended

Mar. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]

	Three Months Ended March 31,
	2014			2013

Risk-free interest rate		2.75	%		0.85	%
Expected volatility		100.72	%		83.41	%
Expected life (in years)		10.00			5.25
Expected forfeiture rate		5	%		5	%
Expected dividend yield		0.0	%		0.0	%

Schedule of Shar-based Compensation, Stock Options and Restricted Stock Awards, Activity [Table Text Block]

	Stock Options					Restricted Stock Awards
Equity Awards	Options Outstanding			Weighted Average Exercise Price		Non-vested Restricted Stock Outstanding			Weighted Average Grant Date Fair Value		Weighted Average Contractual Terms of Equity Awards (in years)

Equity awards outstanding at December 31, 2013		861,905		$	12.30		2,112		$	16.29
Equity awards granted		323,200		$	3.66		4,500		$	3.72
Equity awards exercised	–			–			(6,091	)	$	8.00
Equity awards forfeited, cancelled or expired		(10,555	)	$	34.14	–			–

Equity awards outstanding at March 31, 2014		1,174,550		$	9.72		521		$	4.63		6.95

Aggregate intrinsic value of outstanding awards at March 31, 2014	$	–				$	1,756

Equity awards exercisable at March 31, 2014		779,446		$	12.07							5.74

Aggregate intrinsic value of awards exercisable at March 31, 2014	$	–

Note 11 - Warrants (Tables)

3 Months Ended

Mar. 31, 2014

Warrants [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Warrants	Number of Warrants Issued		Weighted Average Exercise Price

Warrants outstanding at December 31, 2013		3,268,013	$	10.43

Warrants granted in connection with the January 2014 Common Stock Offering, as more fully described in Note 9		1,801,802	$	4.10

Warrants exercised for common stock	–		–

Warrants outstanding at March 31, 2014		5,069,815	$	8.18

Aggregate intrinsic value of outstanding warrants at March 31, 2014	$	-

Weighted average remaining contractual terms (in years)		3.13

Schedule of Common Stock Warrant Liability Valuation Assumptions [Table Text Block]

	March 31, 2014			December 31, 2013

Risk-free interest rate		0.13	%		0.13	%
Expected volatility		64.74	%		64.74	%
Expected life (in years)		1.25			1.25
Expected forfeiture rate		0.0	%		0.0	%
Expected dividend yield		0.00	%		0.00	%

Schedule of Common Stock Warranty Liability [Table Text Block]

Beginning balance as of January 1, 2014	$	3,026
Gain from the adjustment for the change in fair value included in net income		(3,026	)
Ending balance as of March 31, 2014	$	–

Note 4 - Net Loss Per Common Share (Details)	3 Months Ended
Note 4 - Net Loss Per Common Share (Details)	Mar. 31, 2014 shares	Mar. 31, 2013 shares	Dec. 31, 2013 shares	Oct. 28, 2013 shares
Earnings Per Share [Abstract]
Reverse Stock Split, Number of Shares Outstanding Consolidated into Each Share				4.5
Common Stock, Shares, Outstanding	17,217,066		13,604,975	61,226,873
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,244,886	4,685,862

Note 5 - Investment Securities - Available For Sale (Details) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Short Term Investments Available For Sale [Member]
Note 5 - Investment Securities - Available For Sale (Details) [Line Items]
Short-term Investments	$ 47,255,487	$ 37,156,381
Short-term Investments	$ 47,255,487	$ 37,156,381

Note 5 - Investment Securities - Available For Sale (Details) - Short-Term Investment by Bond Maturities - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Within 3 Months [Member]
Corporate bond maturities
Cost	$ 11,798,892	$ 7,799,033
Fair value	11,750,665	7,797,689
Between 3-12 Months [Member]
Corporate bond maturities
Cost	35,484,492	29,401,514
Fair value	35,504,822	29,358,692
Summary of Short Term Investment [Member]
Corporate bond maturities
Cost	47,283,384	37,200,547
Fair value	$ 47,255,487	$ 37,156,381

Note 5 - Investment Securities - Available For Sale (Details) - Investment Securities Gross Unrealized Losses and Fair Value by Investment Category - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Feb. 28, 2013	Mar. 31, 2014	Dec. 31, 2013
Corporate Debt Securities [Member]
Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Bonds – corporate issuances with unrealized gains		$ 4,366,735	$ 6,650,095
Bonds – corporate issuances with unrealized gains		97	1,907
Bonds – corporate issuances with unrealized losses		42,888,752	30,506,286
Bonds – corporate issuances with unrealized losses		(27,994)	(46,073)
Bonds – corporate issuances with unrealized gains	$ 25,000,000
Total		47,255,487	37,156,381
Total		$ (27,897)	$ (44,166)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

Note 5 - Investment Securities - Available For Sale (Details) - Investment Income - USD ($)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Investment Income [Abstract]
Interest and dividend income	$ 27,629	$ 70,303
Realized losses	(20,610)	(53,740)
	$ 7,019	$ 16,563

Note 5 - Investment Securities - Available For Sale (Details) - Component of Accumulated Other Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Component of Accumulated Other Comprehensive Loss [Abstract]
Balance at	$ (44,166)
Unrealized losses on investment securities	(4,341)
Realized loss reclassified from other accumulated comprehensive loss	20,610	$ 53,740
Net other comprehensive loss, net	16,269	$ (31,949)
Balance at	$ (27,897)

- Definition

+ References + Details

Note 6 - Fair Value of Measurements (Details)	3 Months Ended
Note 6 - Fair Value of Measurements (Details)	Mar. 31, 2014 USD ($)
Fair Value Disclosures [Abstract]
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	$ 0
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount	0
Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount	0
Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers out of Level 3	$ 0

Note 6 - Fair Value of Measurements (Details) - Assets and Liabilities at Fair Value on a Recurring Basis - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Inputs, Level 1 [Member]
Assets:
Short-term investments available for sale Bonds – corporate issuances	$ 47,255,487	$ 37,156,381
Fair Value, Inputs, Level 3 [Member]
As of March 31, 2014
Common stock warrant liability		3,026
Short-term investments available for sale Bonds – corporate issuances	$ 47,255,487	37,156,381
Common stock warrant liability		$ 3,026

Note 7 - Accrued Liabilities (Details) - Other Accrued Liabilities - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Other Accrued Liabilities [Abstract]
Amounts due to contract research organizations and other contractual agreements	$ 1,411,249	$ 1,711,934
Accrued payroll and related benefits	661,151	900,434
Accrued professional fees	65,000	63,500
Accrued interest on notes payable	48,438
Other	20,000	31,785
Total accrued liabilities	$ 2,205,838	$ 2,707,653

Note 8 - Note Payable (Details)	Nov. 25, 2013 $ / shares
Warrant [Member] \| Hercules [Member] \| Hercules Credit Agreement [Member]
Note 8 - Note Payable (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 3.59

Note 8 - Note Payable (Details) - Future Principal Payments Due on the Credit Agreement	Mar. 31, 2014 USD ($)
Future Principal Payments Due on the Credit Agreement [Abstract]
2015	$ 439,218
2016	1,878,096
2017	2,104,767
2018	577,919
Total	$ 5,000,000

Note 9 - Stockholders' Equity (Details) $ / item in Millions, $ in Millions		1 Months Ended
	Feb. 26, 2013 USD ($) shares	Feb. 25, 2013 $ / item
Dominick LLC [Member] \| February 2013 Preferrd Stock Offering [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance or Sale of Equity (in Dollars) \| $	$ 15.0
Aggregate Proceeds Of 10 Million Dollars [Member] \| January 2011 Preferred Stock Offering [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Convertible Preferred Stock, Shares Reserved for Future Issuance	2,682,764
Minimum 4 Dollar Share Price [Member] \| February 2013 Preferrd Stock Offering [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,341,382
January 2011 Preferred Stock Offering [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Unit Price (in Dollars per Item) \| $ / item		25
Commission on Proceeds from ATM Shares, Percent		3.00%
February 2013 Preferrd Stock Offering [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Warrants Issued Expiration Period	5 years

Note 9 - Stockholders' Equity (Details) - Assumptions Used in the Valuation of the Warrants Associated with Preferred Stock Offering	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Warrant [Member]
Note 9 - Stockholders' Equity (Details) - Assumptions Used in the Valuation of the Warrants Associated with Preferred Stock Offering [Line Items]
Risk-free interest rate	0.78%
Expected volatility	102.23%
Expected life (in years)	5 years
Expected forfeiture rate	0.00%
Expected dividend yield	0.00%
Risk-free interest rate	2.75%	0.85%
Expected volatility	100.72%	83.41%
Expected life (in years)	10 years	5 years 3 months
Expected forfeiture rate	5.00%	5.00%
Expected dividend yield	0.00%	0.00%

Note 10 - Stock Based Compensation (Details) - USD ($)	3 Months Ended		12 Months Ended		15 Months Ended
Note 10 - Stock Based Compensation (Details) - USD ($)	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2010	Mar. 31, 2014	Oct. 28, 2013	Dec. 31, 2007	Jun. 13, 2007
Subsequent Event [Member]
Note 10 - Stock Based Compensation (Details) [Line Items]
Share Based Compensation, Options and Restricted Stock, Outstanding						3,720,000
Stock Incentive Plan 2007 [Member]
Note 10 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							148,148
Allocated Share-based Compensation Expense (in Dollars)	$ 607,230	$ 263,192
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	$ 1,200,000				$ 1,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$ 3.31	$ 3.92
Restricted Stock [Member]
Note 10 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	4,500	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 346 days				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,189,528		944,444	444,444	1,189,528			222,222
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			500,000	222,222
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 36 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	4,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,175,071
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	14,457				14,457

Note 10 - Stock Based Compensation (Details) - Fair Value of Option Assumptions	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Fair Value of Option Assumptions [Abstract]
Risk-free interest rate	2.75%	0.85%
Expected volatility	100.72%	83.41%
Expected life (in years)	10 years	5 years 3 months
Expected forfeiture rate	5.00%	5.00%
Expected dividend yield	0.00%	0.00%

Note 10 - Stock Based Compensation (Details) - Stock Option and Restricted Stock Awards	3 Months Ended	15 Months Ended
	Mar. 31, 2014 $ / shares shares	Mar. 31, 2014 $ / shares shares
Stock Option and Restricted Stock Awards [Abstract]
Equity awards outstanding at December 31, 2013	861,905
Equity awards outstanding at December 31, 2013 (in Dollars per share) \| $ / shares	$ 12.30
Equity awards outstanding at December 31, 2013	2,112
Equity awards outstanding at December 31, 2013 (in Dollars per share) \| $ / shares	$ 16.29
Equity awards granted	323,200
Equity awards granted (in Dollars per share) \| $ / shares	$ 3.66
Equity awards granted	4,500
Equity awards granted (in Dollars per share) \| $ / shares	$ 3.72
Equity awards exercised	(6,091)
Equity awards exercised (in Dollars per share) \| $ / shares	$ 8.00
Equity awards forfeited, cancelled or expired	(10,555)
Equity awards forfeited, cancelled or expired (in Dollars per share) \| $ / shares	$ 34.14
Equity awards outstanding at March 31, 2014	1,174,550	1,174,550
Equity awards outstanding at March 31, 2014 (in Dollars per share) \| $ / shares	$ 9.72	$ 9.72
Equity awards outstanding at March 31, 2014	521	521
Equity awards outstanding at March 31, 2014 (in Dollars per share) \| $ / shares	$ 4.63	$ 4.63
Equity awards outstanding at March 31, 2014	6 years 346 days	10 years
Aggregate intrinsic value of outstanding awards at March 31, 2014	1,756	1,756
Equity awards exercisable at March 31, 2014	779,446	779,446
Equity awards exercisable at March 31, 2014 (in Dollars per share) \| $ / shares	$ 12.07	$ 12.07
Equity awards exercisable at March 31, 2014	5 years 270 days

Note 11 - Warrants (Details)	1 Months Ended
Note 11 - Warrants (Details)	Sep. 30, 2009
Minimum [Member]
Note 11 - Warrants (Details) [Line Items]
Common Stock Warrants Weighted Average Remaining Contractual Term	6 months
Maximum [Member]
Note 11 - Warrants (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	66 months

Note 11 - Warrants (Details) - Summary of Warrant Activity	3 Months Ended
	Mar. 31, 2014 $ / shares $ / item shares
Hercules Credit Agreement [Member]
Note 11 - Warrants (Details) - Summary of Warrant Activity [Line Items]
Warrants granted in connection with the January 2014 Common Stock Offering, as more fully described in Note 9	1,801,802
Warrants granted in connection with the January 2014 Common Stock Offering, as more fully described in Note 9 (in Dollars per share) \| $ / shares	$ 4.10
Warrants outstanding at December 31, 2013	3,268,013
Warrants outstanding at December 31, 2013 (in Dollars per Item) \| $ / item	10.43
Warrants outstanding at March 31, 2014	5,069,815
Warrants outstanding at March 31, 2014 (in Dollars per Item) \| $ / item	8.18
Weighted average remaining contractual terms (in years)	3 years 47 days

Note 11 - Warrants (Details) - Fair Value of Warrants Assumptions	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Fair Value of Warrants Assumptions [Abstract]
Risk-free interest rate	0.13%	0.13%
Expected volatility	64.74%	64.74%
Expected life (in years)	1 year 3 months	1 year 3 months
Expected forfeiture rate	0.00%	0.00%
Expected dividend yield	0.00%	0.00%

Note 11 - Warrants (Details) - Common Stock Warrant Liability	3 Months Ended
	Mar. 31, 2014 USD ($)
Common Stock Warrant Liability [Abstract]
Common Stock Warrant Liability	$ 3,026
Gain from the adjustment for the change in fair value included in net income	$ (3,026)

Note 12 - Contingent Liabilities and Commitments (Details)	1 Months Ended
	Apr. 30, 2012 USD ($)	Jul. 31, 2011 ft²	Mar. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Apr. 30, 2013 USD ($)
Lawrenceville, New Jersey [Member]
Note 12 - Contingent Liabilities and Commitments (Details) [Line Items]
Area of Real Estate Property (in Square Feet) \| ft²		10,870
Lessee Leasing Arrangements, Operating Leases, Term of Contract		66 months
Number of Months in Which Free Rent is Provided		6 months
Payments for Rent	$ 23,000
Standby Letters of Credit [Member]
Note 12 - Contingent Liabilities and Commitments (Details) [Line Items]
Contractual Obligation	250,000
Contractual Obligation Reduction	50,000
Contractual Obligation Nineteen Months from Initial Term	50,000
Contractual Obligation Thirty One Months from Initial Term	50,000
Contractual Obligation Forty Three Months from Initial Term	50,000
Contractual Obligation Remaining	100,000
Contractual Obligation			$ 1,411,249	$ 1,711,934
Escrow Deposit Related To Operating Lease	$ 250,000
Reduction of Escrow Deposit					$ 50,000

Note 13 - Technology Development and Licensing Agreements (Details) - USD ($)		1 Months Ended	3 Months Ended
	Jan. 18, 2013	Jan. 31, 2011	Mar. 31, 2013	Dec. 31, 2008	Mar. 31, 2014
Preferred Equity Financing [Member]
Note 13 - Technology Development and Licensing Agreements (Details) [Line Items]
Proceeds from Issuance of Convertible Preferred Stock		$ 2,000,000
Requires Enrollment Of Patients [Member]
Note 13 - Technology Development and Licensing Agreements (Details) [Line Items]
Proceeds from Issuance of Convertible Preferred Stock		2,000,000
Other Receivables					$ 371,000
Proceeds from License Fees Received	$ 5,000,000			$ 2,500,000
Deferred Revenue			$ 5,000,000
Deferred Revenue Amortization Period			10 years
Proceeds from Issuance of Convertible Preferred Stock		$ 4,000,000
Percentage Reduction On Milestone Payments		40.00%

Label	Element	Value
Dividends Payable, Current	us-gaap_DividendsPayableCurrent	$ 4,600,000
WarrantsIssuedExpirationPeriod	clsn_WarrantsIssuedExpirationPeriod	7 years
Investment Warrants, Exercise Price	invest_InvestmentWarrantsExercisePrice	$ 23.58
NoteStockConversionRate	clsn_NoteStockConversionRate	3.00%
CommonStockAndWarrantsIssuedShares	clsn_CommonStockAndWarrantsIssuedShares	448,478
Line of Credit Facility, Maximum Borrowing Capacity	us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity	$ 10,000,000
Proceeds from Issuance of Warrants	us-gaap_ProceedsFromIssuanceOfWarrants	$ 7,100,000
Share Price	us-gaap_SharePrice	$ 4.1625
LoanTrancheAmount	clsn_LoanTrancheAmount	$ 5,000,000
ProceedsFromIssuanceOfWarrantsNet	clsn_ProceedsFromIssuanceOfWarrantsNet	6,300,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	15,000,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	9,800,000
Deferred Finance Costs, Net	us-gaap_DeferredFinanceCostsNet	$ 217,715
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	3,603,604
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	1,195,927
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	1,392,109
Debt Conversion, Converted Instrument, Warrants or Options Issued	us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	11,415
Interest Expense, Debt	us-gaap_InterestExpenseDebt	$ 146,874
Conversion of Stock, Shares Converted	us-gaap_ConversionOfStockSharesConverted1	2,682,764
Amortization of Financing Costs	us-gaap_AmortizationOfFinancingCosts	$ 31,560
Legal Fees	us-gaap_LegalFees	50,000
Warrants and Rights Outstanding	us-gaap_WarrantsAndRightsOutstanding	5,400,000
Warrants and Rights Outstanding	us-gaap_WarrantsAndRightsOutstanding	0
Warrants and Rights Outstanding	us-gaap_WarrantsAndRightsOutstanding	$ 3,026
Class of Warrant or Right, Exercise Price of Warrants or Rights	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	1,801,802
Class of Warrant or Right, Exercise Price of Warrants or Rights	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	4.10
Class of Warrant or Right, Exercise Price of Warrants or Rights	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	5.31
Warrant [Member]
Deferred Finance Costs, Net	us-gaap_DeferredFinanceCostsNet	$ 521,763
Warrant [Member]
Deferred Finance Costs, Net	us-gaap_DeferredFinanceCostsNet	$ 73,654
Hercules Credit Agreement [Member]
Fair Value Assumptions, Expected Volatility Rate	us-gaap_FairValueAssumptionsExpectedVolatilityRate	102.00%
Fair Value Assumptions, Risk Free Interest Rate	us-gaap_FairValueAssumptionsRiskFreeInterestRate	1.37%
Fair Value Assumptions, Exercise Price	us-gaap_FairValueAssumptionsExercisePrice	$ 3.55
Fair Value Assumptions, Expected Term	us-gaap_FairValueAssumptionsExpectedTerm	5 years
Deferred Finance Costs, Net	us-gaap_DeferredFinanceCostsNet	$ 352,378
Interest Expense, Debt	us-gaap_InterestExpenseDebt	140,625
Amortization of Financing Costs	us-gaap_AmortizationOfFinancingCosts	$ 89,676
Credit Agreement [Member]
Fair Value Assumptions, Expected Volatility Rate	us-gaap_FairValueAssumptionsExpectedVolatilityRate	74.30%
Fair Value Assumptions, Risk Free Interest Rate	us-gaap_FairValueAssumptionsRiskFreeInterestRate	1.10%
Fair Value Assumptions, Expected Term	us-gaap_FairValueAssumptionsExpectedTerm	3 years 6 months
Oxford And Horizon Credit Agreement [Member] \| Contract Termination [Member]
Repayments of Debt and Capital Lease Obligations	us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations	$ 4,100,000
Term A Loan [Member]
Common stock, par value (in Dollars per share)	us-gaap_CommonStockParOrStatedValuePerShare	$ 13.14
Debt Instrument, Interest Rate, Stated Percentage	us-gaap_DebtInstrumentInterestRateStatedPercentage	11.75%
ATM Agreement [Member]
CommonStockSharesPerWarrant	clsn_CommonStockSharesPerWarrant	6,800,000
Oxford And Horizon [Member]
Repayments of Lines of Credit	us-gaap_RepaymentsOfLinesOfCredit	$ 4,000,000
Hercules [Member] \| Hercules Credit Agreement [Member]
Debt Instrument, Basis Spread on Variable Rate	us-gaap_DebtInstrumentBasisSpreadOnVariableRate1	11.25%
Line of Credit Facility, Maximum Borrowing Capacity	us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity	$ 20,000,000
LoanTrancheAmount	clsn_LoanTrancheAmount	5,000,000
Line of Credit Facility, Remaining Borrowing Capacity	us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity	$ 15,000,000
Debt Conversion, Converted Instrument, Warrants or Options Issued	us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	194,986
Series A Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0.25
Series B Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0.25
Closing Price Per Share [Member]
Common stock, par value (in Dollars per share)	us-gaap_CommonStockParOrStatedValuePerShare	$ 12.60
Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	15,000.00422
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	15,000.00422
November 2011 Capital Lease [Member]
Debt Instrument, Periodic Payment	us-gaap_DebtInstrumentPeriodicPayment	$ 5,651
Capital Leased Assets, Gross	us-gaap_CapitalLeasedAssetsGross	144,448
Repayments of Long-term Capital Lease Obligations	us-gaap_RepaymentsOfLongTermCapitalLeaseObligations	$ 11,303